Research activity

Also check out my profile at Research Gate.

*Excluding those that were later published as journal papers.

Research evaluation

Source Total citations received h-index
Google Scholar 73 6
Scopus 34 3
Web of Knowledge 17 2

Journal papers

Contributions are listed by topic and sorted by publication date in reverse chronological order. The most relevant contributions are starred using .

Optimization in quality control and engineering

García-Díaz JC, Pulido-Rojano A, Giner-Bosch V (2017): Bi-objective optimisation of a multihead weighing process. European Journal of Industrial Engineering, 11(3):403–423.   DOI:10.1504/EJIE.2017.084882 ]
Impact factor (2017): 1.085. JCR ranking: 61/84.
Citations received: 3

Giner-Bosch V, San Matías S, Clemente-Císcar M, Carrión A (2016): Optimal Design of Pre-control Plans. Quality and Reliability Engineering International, 32(2):623–634.   DOI:10.1002/qre.1777 ]
Impact factor (2016): 1.366. JCR ranking: 34/85.
Citations received: 3

Clinical biostatistics

Gil-Raga M, Jantus‑Lewintre E, Gallach S, Giner Bosch V, Frangi‑Caregnato A, Safont‑Aguilera MJ, Garde-Noguera J, Zorraquino‑Pina E, García‑Martínez M, Camps-Herrero C (2018): Molecular subtypes in early colorectal cancer associated with clinical features and patient prognosis. Clinical and Translational Oncology, 20(11):1422–1429.   DOI:10.1007/s12094-018-1874-8 ]
Impact factor (2017): 2.392. JCR ranking: 156/223.

Gasent Blesa JM, Poquet Jornet JE, Garde J, Giner Bosch V, Soler Tortosa M, Cuesta Grueso C, Fonfría Esparza M, Munilla Das A, Olmo Ortega P, Clemente M, San Matías S, Colio JM, Alberola Candel V (2014): Cisplatin, docetaxel and 5 fluoracil followed by pegfilgrastrim support and cisplatin in head and neck cancer. Atención Farmacéutica-European Journal of Clinical Pharmacy, 16(6):399–408. ]

Gasent Blesa JM, Poquet Jornet J, Giner Bosch V, Cuesta Grueso C, Munilla Das A, Garde Noguera J, Fonfría Esparza M, Olmo Ortega P, Alberola Candel V (2014): Chemotherapy-induced anemia treated with erythropoietin alpha or dabopoetin in non-small cell lung cancer patients. Atención Farmacéutica-European Journal of Clinical Pharmacy, 16(5):339–345. ]

Gasent Blesa JM, Garde Noguera J, Laforga Canales JB, Giner Bosch V, Alberola A, Soler Tortosa M, Peris Godoy M, Sanchez JL, Provencio Pulla M, Alberola Candel V (2012): Phase II Trial of Concomitant Neoadjuvant Chemotherapy with Oxaliplatin and Capecitabine and Intensity-Modulated Radiotherapy (IMRT) in Rectal Cancer. Journal of Gastrointestinal Cancer, 43(4):553–561.   DOI:10.1007/s12029-012-9364-7 ]
Citations received: 9

Gasent Blesa JM, Giner Marco V, Giner-Bosch V, Cerezuela Fuentes P, Alberola Candel V (2011): Phase II trial of oxaliplatin and capecitabine after progression to first-line chemotherapy in androgen-independent prostate cancer patients. American Journal of Clinical Oncology, 34(2):155–159.   DOI:10.1097/COC.0b013e3181d6b453 ]
Impact factor (2011): 2.005. JCR ranking: 123/193.
Citations received: 19

San Matías S, Clemente M, Giner-Bosch V (2011): Classification Models for Predicting a Patient Clinical Status: Discussion on the Case of Chemotherapy-induced Neutropenia Duration. Treatment Strategies - Oncology, 2(2):124–127. ]

San Matías S, Clemente M, Giner-Bosch V, Giner V (2011): Predicting the duration of chemotherapy-induced neutropenia: new scores and validation. Annals of Oncology, 22(1):181–187.   DOI:10.1093/annonc/mdq332 ]
Impact factor (2011): 6.425. JCR ranking: 18/196.
Citations received: 7

Gasent Blesa JM, Alberola Candel V, Giner Marco V, Giner-Bosch V, Provencio Pulla M, Laforga Canales JB (2010): Experience with fulvestrant acetate in castration-resistant prostate cancer patients. Annals of Oncology, 21(5):1131–1132.   DOI:10.1093/annonc/mdq010 ]
Impact factor (2010): 6.452. JCR ranking: 20/185.
Citations received: 10

Data mining applied to customer management

Clemente-Císcar M, San Matías S, Giner-Bosch V (2014): A methodology based on profitability criteria for defining the partial defection of customers in non-contractual settings. European Journal of Operational Research, 239(1):276–285.   DOI:10.1016/j.ejor.2014.04.029 ]
Impact factor (2014): 2.358. JCR ranking: 10/81.
Citations received: 3

Demography and mortality

Giner-Bosch V, Cabrerizo-Cabanos M, Debón-Aucejo A (2016): On the use of Statistical Process Control in Monitoring Mortality. An Application to European Countries. Estadística Española, 58(191):265–275.

Indexed conference contributions

Gil Raga M, Gallach S, Jantus-Lewintre E, Safont MJ, García Martínez ML, Garde-Noguera J, Ruiz Carmona MD, Blasco S, Giner-Bosch V, Camps C (2016): Molecular subtyping of colon cancer (CC) based on mutational status of RAS, BRAF, and DNA mismatch repair (MMR) proteins. Prognostic value. Annual Meeting of the American Society of Clinical Oncology, ASCO 2016, 03–07/06/2016, Chicago, IL. Journal of Clinical Oncology, 34(15):Se15094.  DOI:10.1200/JCO.2016.34.15_suppl.e15094 ]
Citations received: 1

Pulido-Rojano A, García-Díaz JC, Giner-Bosch V (2015): A multiobjective approach for optimization of the multihead weighing process. International Conference on Industrial Engineering and Systems Management, IEEE IESM 2015, 21–23/10/2015, Sevilla. Proceedings of 2015 International Conference on Industrial Engineering and Systems Management, IEEE IESM 2015, 426–434.  DOI:10.1109/IESM.2015.7380192 ]
Citations received: 8

Gasent Blesa JM, Giner Marco V, Alberola Candel V, Juan Ó, Giner-Bosch V, López A, Provencio Pulla M, Grande Pulido E (2009): Effect of the response to first-line chemotherapy (chemo) in the chemotherapy-induced anemia control with the administration of Erithropoyetins (Epos) in metastatic non-small cell lung cancer (NSCLC) patients (pt). 45th Annual Meeting of the American Society of Clinical Oncology, 29/05–02/06/2009, Orlando, FL. Journal of Clinical Oncology, 27(15):Se20647.

San Matías S, Giner-Bosch V (2009): Optimal Pre-control as a tool to monitor the reliability of a manufacturing system. European Safety and Reliability Conference (ESREL)/17th Annual Meeting of the Society for Risk Analysis Europe (SRA-Europe), 22–25/09/2008, Valencia. Safety, Reliability and Risk Analysis: Theory, Methods and Applications, 4:2735–2741.

Technical reports

Clemente M, Giner-Bosch V, San Matías S (2012): Assessing classification methods for churn prediction by composite indicators. Tech. Report, DEIOAC-2012-02. Department of Applied Statistics, Operations Research and Quality, Universitat Politècnica de València. ]
Citations received: 8

San Matías S, Giner-Bosch V (2010): Selection of Best Pre-Control Technique by Optimization Tools. Tech. Report, DEIOAC-2010-06. Department of Applied Statistics, Operations Research and Quality, Universitat Politècnica de València. ]
Citations received: 2

PhD Thesis

Giner-Bosch V (2014): Precontrol óptimo. Caracterización, análisis y técnicas de resolución. PhD Thesis, Universitat Politècnica de València. [In Spanish] ]